Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guretolimod Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumors
NCT03416335Phase 2Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of guretolimod in solid tumor (advanced stage), head and neck squamous cell carcinoma (HNSCC), sponsored by Sumitomo Pharma America. Started Jun 2018; status: terminated.
02
Drugs
guretolimod
03
Conditions
solid tumor (advanced stage)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03416335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03416335.